Anglerfish (Lophius piscatorius) Brockmann organs contain a form of somatostatin-14, identical to the hypothalamic tetradecapeptide, and two distinct forms of somatostatin-28, which can be separated by reversed-phase highpressure liquid chromatography (HPLC). Analysis of the NH2-terminal amino acid sequence and comparison of the ability to incorporate 1251 indicate that one of these forms corresponds to an octacosapeptide including in its sequence the (Tyr-7, Gly-10) derivative of somatostatin-14 (somatostatin II). Exposure of this somatostatin-28 species to an endopeptidase activity from the rat brain cortex generates a peptide immunologically related to somatostatin and undistinguishable from synthetic (Tyr-7, Gly-10) somatostatin-14 II by HPLC. This somatostatin-28 II exhibits a potent inhibitory effect on growth hormone release by rat anterior pituitary cells, comparable to the other somatostatin-28 form. Since (Tyr-7, Gly-10) somatostatin-14 II cannot be detected in anglerfish pancreatic islets, these results indicate that somatostatin-28 II represents the terminal active product of prosomatostatin II processing, whose structure was predicted from the cDNA nucleotide sequence corresponding to the second mRNA cloned from ang-
Somatostatin-14, a peptide first discovered in the hypothalamus (1), appears to be present in mammals with an octacosapeptide form (somatostatin-28) in both the neural and gastrointestinal tracts (2) (3) (4) (5) . Both forms represent the COOH-terminal portion of the common higher molecular weight (Mr, =15,000) biosynthetic precursor (6, 7) .
Expression of gene(s) encoding somatostatin in the pancreatic islets of the teleostean fish Lophius piscatorius (anglerfish) appears to be complex. A multigene family was suggested from the polydispersity of the products obtained from in vitro translation of islet mRNA (8) . Cloning two cDNAs indicated that, in addition to a mRNA encoding the precursor of a tetradecapeptide identical to the hypothalamic hormone (prosomatostatin I), a second messenger predicts the synthesis of a second precursor (7) containing in its COOHterminal end the sequence of a (Tyr-7, Gly-10) derivative of somatostatin-14 (somatostatin-14 II) (7) . Analysis made on extracts from hypothalamic tissue gave no evidence for this second gene product (6, 9) , but recent results suggested that this second peptide might be included in a larger precursor form in anglerfish pancreas (10, 11) .
In the present investigation, biochemical evidence is presented to show that this (Tyr-7, Gly-10) somatostatin-14 II is expressed as a somatostatin-28 form (somatostatin-28 II). This octacosapeptide is highly potent on the inhibition of growth hormone release by pituitary cells, and possibly represents the final active product of prosomatostatin II posttranslational conversion.
MATERIALS AND METHODS
Brockmann organs from anglerfish (Lophius piscatorius) (12) were collected from live animals directly on the fishing boat (thanks to the kind cooperation of captain Riou and his crew; La Marie-Sophie, Le Conquet, Finistere, France) and were immediately frozen in liquid nitrogen. They were further stored at -80'C until used.
Islets were homogenized and extracted in 0.1 M HCl/8 M urea, and the extract was passaged on a Sephadex G-50 column as described (6, 13) . Radioimmunoassay (RIA) was carried out as described (6), using antiserum 36-38 directed toward the COOH-terminal portion of somatostatin-14, and recognizing both the reference tetradecapeptide and its (Tyr-7, Gly-10) derivative (6) . Counting of 12 I was done using a Kontron Analytical MDA 312 y counter.
The high-pressure liquid chromatography (HPLC) system consisted of an SP 8000 (Spectra Physics, Santa Clara, CA) apparatus. Reversed-phase HPLC was carried out with a 10 RP 8 Lichrosorb column from Merck, as described in the figure legends. A Kratos SF 740 UV detector (Schoeffel) was used for monitoring peptides in column effluents.
125I-labeling was by the lactoperoxidase method (14) . Free iodine was separated from 1251-labeled peptides by means of filtration through a Sep Pak C18 cartridge (Waters Associates) as indicated.
Immunoprecipitation of labeled products was performed using an excess of 36-38 antiserum in the RIA buffer containing 1% Triton X-100, either in the presence or in the absence of unlabeled somatostatin-14. Precipitation of the immune complex was conducted by the double antibody procedure using anti-rabbit IgG raised in the goat.
NH2-terminal amino acid analysis was carried out by both the dansyl chloride (15) and the p-dimethylaminoazobenzene 4'-isothiocyanate/phenylisothiocyanate double-coupling methods (16) .
Processing experiments were conducted using a proteolytic enzyme activity isolated from the rat brain cortex, as reported elsewhere (17) . After digestion, the products were evaporated in a Speed Vacuum (Savant) and redissolved in 1 M acetic acid prior to HPLC analysis, which was done as described in the figure legends.
Synthetic C02/95% air. After 3 days, the cells were first washed twice with DME medium containing 0.1% bovine serum albumin then exposed to the various somatostatin species in the same medium for 3 hr. The growth hormone level was measured by RIA on the medium of each well using the NIADDK kit from Parlow A. (provided by the National Hormone and Pituitary Program). RESULTS Molecular sieve filtration of extracts from L. piscatorius Brockmann bodies on a Sephadex G-50 column generated the now classical pattern (6, 9, 19) exhibiting three distinct somatostatin immunoreactive peaks (Fig. 1) . The two major low molecular weight species were assumed to represent, respectively, pancreatic anglerfish somatostatin-28 and somatostatin-14 as they coelute with hypothalamic standards during gel filtration. Since cDNA cloning has predicted the existence of at least two distinct somatostatin genes (7) encoding distinct prosomatostatins (prosomatostatins I and II), which notably differ in both the somatostatin-28 and somatostatin-14 primary sequences, we have tested for this possibility by analyzing further each of the low molecular weight somatostatin forms.
Eluate corresponding to the putative somatostatin-14 anglerfish species was pooled and applied to a Lichrosorb 10 RP 8 column eluted in a solvent system calibrated with synthetic peptides and the complete resolution of (Tyr-7, Gly-10) somatostatin-14, somatostatin-14 II from somatostatin-14 I was allowed. After elution, both the initial somatostatin immunoreactivity and optical density were recovered as a unique sharp peak eluting at the position of reference hypothalamic somatostatin-14. Since both anglerfish pancreatic somatostatin-14 I and hypothalamic somatostatin-14 have identical primary sequences (20), we thus confirmed and extended previous evidence of the absence of somatostatin-14 II (10 (Fig. 1) were pooled. An aliquot was applied to a 10 RP 8 Lichrosorb column (4 x 250 mm) and eluted with a mixture of acetonitrile/0. 1 % trifluoroacetic acid (vol/vol) in H20/0.1% trifluorocetic acid (vol/vol). A linear gradient from 28% to 33% acetonitrile was used at 1 ml/min in 30 min. Each fraction (1 ml) was assayed for somatostatin immunoreactivity; results (histogram) are expressed in ng of somatostatin-14 per ml. Continuous line represents the absorbance of eluate monitored at 215 nm (the sensitivity was set at 0.01 absorbance unit full scale).
processed through similar conditions (Fig. 2) , two distinct immunoreactive peaks corresponding with 2 peaks of optical absorbance were found, the second one being twice as intense as the first. Identical patterns were consistently obtained using various extraction and elution conditions (not shown). This immunoreactive material was found to behave as synthetic hypothalamic somatostatin-28 during subsequent Sephadex G-50 filtration (not shown). Purification of each form, freed from the other, was achieved through successive, preparative, HPLC runs (Fig. 2) , with manual collection to decrease cross-contamination between the two peaks (Fig. 3) .
Since these two forms might represent, respectively, somatostatin-28 I and somatostatin-28 II, we thus have tested this hypothesis by using some of the differences in their respective predicted primary sequences somatostatin-28 I and somatostatin-28 11 (7) . First, the presence of a tyrosine in E U.W(J) 10 20 30
Time, min  FIG. 3 . Separation by HPLC of the two somatostatin-28 forms isolated from Brockmann organs. The somatostatin-28 species recovered from the Sephadex G-50 column (Fig. 1) were first eluted as in Fig. 2 . Each separated immunoreactive peak (I and II) was collected manually and then rerun on the same HPLC system. Isolation was achieved by successive HPLC steps using the same methodology. A typical result is shown: upper trace represents elution of the isolated somatostatin-28 from peak II; lower trace is somatostatin-28 from peak I. Proc. NatL. Acad Sci USA 81 (1984) 7005 position 21 in the sequence of somatostatin-28 II and the absence of tyrosine in somatostatin-28 I predicted a differential reactivity of those peptides toward iodination. Each species was exposed to 12 I-labeled Na using the lactoperoxidase technique, and the products were further analyzed for their ability to bind anti-somatostatin antibodies 36-38 (Table 1) in either the absence or the presence of a large excess of unlabeled hypothalamic somatostatin-14. As shown in Table 1 , only one of the two peptides (peak II in Fig. 3 ) was specifically recognized by somatostatin antiserum. No labeling of the other form was detectable, as could be further demonstrated by HPLC analysis of the two 1251 reaction products (not shown). Second, NH2-terminal sequence determination of each of these forms was achieved using both the dansyl procedure (15) and two manual cycles of the double coupling method (16) . By these methods, the first two amino acid residues of peak II (Ser-Val) and peak I (Ala-Ala) were identified. Therefore, peaks I and II fulfill the criteria needed for their identification as somatostatin-28 I and somatostatin-28 II, respectively: (i) the identity of behavior with hypothalamic somatostatin-28 during gel filtration; (it) the recognition by somatostatin antibodies, which react specifically with the last four common amino acid residues of the somatostatin-14 sequence; (iii) the presence of a tyrosine in one species and the lack of such a residue in the other; and (iv) the identity of the NH2-terminal sequence of each species with that predicted by the cDNA nucleotide structures (7).
Furthermore, when somatostatin-28 II was exposed to an enzymatic activity that specifically cleaves hypothalamic somatostatin-28 into somatostatin-14 (17) and the resulting mixture was analyzed, after a 4.5-hr incubation, by HPLC (Fig. 4) Peak II 75% 2% After l25l-labeling of the isolated peaks I and II (from Fig. 3 ) free iodine was eliminated through a Sep Pak C18 cartridge (Waters Associates) and the 'l25-labeled peptides were eluted with aqueous acetonitrile containing 0.1% trifluoroacetic acid (80:20; vol/vol). After evaporation of the solvent, 10,000 cpm of each compound was redissolved in the RIA buffer and incubated in the presence of excess 36-38 antiserum for 20 hr at 40C either in the presence, or in the absence, of unlabeled somatostatin-14 (S-14) (10 ,Lg) as competitor. Immune complexes were precipitated using the double-antibody technique. Results are expressed as percentage of total counts recovered in the precipitate made in the absence of competitor. 4 . HPLC analysis of enzymatic conversion of somatostatin-28 II into (Tyr-7, Gly-10) somatostatin-14. The purified somatostatin-28 from peak II (Fig. 3) Although a direct conversion of prosomatostatin I into somatostatin-14 I by cleavage at the dibasic doublet level cannot be formally excluded, the data reported above give indirect support to a metabolic pathway in which prior conversion to somatostatin-28 is an obligatory intermediate. Isolation and characterization of the enzyme(s) possibly involved in these cleavages will probably contribute to shed some light on the whole mechanism.
Note Added in Proof. The complete amino acid sequence of the here described somatostatin-28 II was determined (24) . The primary structure is in total agreement with the one predicted from cDNA sequencing (7) .
